Liver Toxicity Risk Management Should Consider Timing Of Safety Signal, FDAer Says
This article was originally published in The Pink Sheet Daily
Surveillance strategies should take into account whether drug-induced hepatotoxicity is “front-loaded” soon after initiating therapy or after a longer-term exposure threshold has been reached, Division of Drug Risk Evaluation Director Avigan says.
You may also be interested in...
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.
Acquisition will enable company to leverage "end-to-end" product development through post-commercialization offerings, company says. Omnicare is now in discussions with NeighborCare after raising its takeover bid to $1.55 bil.